Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children

This study has been completed.
Johns Hopkins Bloomberg School of Public Health
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID) Identifier:
First received: November 25, 2009
Last updated: December 31, 2012
Last verified: December 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2011
  Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)